Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cereno Scientific AB Series B
CRNO-BCurrent price
5 SEK
+0.06 SEK (+1.21%)
Last closed
4.94 SEK
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Stockholm Exchange
Capitalization
1 390 364 464 SEK
Yield for 12 month
+15.21 %
1Y
3Y
5Y
10Y
15Y
CRNO-B
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden. Address: BioVentureHub, Gothenburg, Sweden, 431 83
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
144.55 SEKP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
+49 960 789 SEK
Last Year
+58 336 911 SEK
Current Quarter
+24 223 532 SEK
Last Quarter
+21 912 467 SEK
Key Figures CRNO-B
1 year
3 years
5 years
10 years
EBITDA
-63 241 130 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-13.17 %
PEG Ratio
–
Return On Equity TTM
-27.73 %
Wall Street Target Price
144.55 SEK
Revenue TTM
69 678 222 SEK
Book Value
0.91 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
124.8 %
Dividend Yield
–
Gross Profit TTM
58 336 908 SEK
Earnings per share
-0.28 SEK
Diluted Eps TTM
-0.28 SEK
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-101.1 %
Dividend Analytics CRNO-B
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CRNO-B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CRNO-B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
19.9541
Enterprise Value EBITDA
-7.1997
Price Book MRQ
5.4098
Financials CRNO-B
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CRNO-B
For 52 weeks
3.45 SEK
9.63 SEK
50 Day MA
6.05 SEK
Shares Short Prior Month
–
200 Day MA
5.17 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart